Liposarcoma cells with aldefluor and CD133 activity have a cancer stem cell potential

Stratford, Eva W.; Castro, Russell; Wennerstrøm, Anna B.; Holm, Ruth; Munthe, Else; Lauvrak, Silje Ugland; Bjerkehagen, Bodil; Myklebost, Ola

doi:10.1186/2045-3329-1-8

Cited by 22 publications

(22 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Stratford et al (2011) have identified candidate sarcoma CSCs in a liposarcoma cell line (SW872) after double enrichment for CD133 and ALDH High activity (ALDH High ). Cells doubly positive for CD133 and ALDH High were more clonogenic and tumorigenic when compared to parental cells or cells singly positive for either CD133 or ALDH High .…”

Section: Sarcoma Stem Cellsmentioning

confidence: 99%

Cancer Stem Cells in Pediatric Sarcomas

Cruz¹

2013

Front. Oncol.

View full text Add to dashboard Cite

Sarcomas represent a clinically and biologically diverse group of malignant connective tissue tumors. Despite aggressive conventional therapy, a large proportion of sarcoma patients experience disease recurrence which will ultimately result in mortality. The presence of a unique population of cells, referred to as cancer stem cells (CSCs), have been proposed to be responsible for refractory responses to current chemotherapies as well underlying the basis for metastasis and relapse of disease – clinical corollaries to what has been termed the CSC hypothesis. The presence of CSCs have been suggested in a variety of hematologic and solid malignancies, and only more recently in sarcomas. Based on our current understanding of normal stem cell biology and evidence obtained from the study of malignant hematopoietic and solid tumors, researchers have identified candidate cell surface markers (CD133, CD117, Stro-1), biochemical markers (aldehyde dehydrogenase activity), and cytological characteristics (side population and spherical colony formation) that may identify putative sarcoma CSCs. In this review, we explore the current state of evidence that may suggest the existence of sarcoma CSCs. We present research in osteosarcoma, the Ewing’s sarcoma family of tumors, rhabdomyosarcoma, as well as other sarcoma subtypes to describe commonly used molecular and biochemical markers, as well as techniques, used in the identification, isolation, and characterization of candidate sarcoma CSCs. We will also discuss the current controversies and challenges that face research in sarcoma CSC.

show abstract

Section: Sarcoma Stem Cellsmentioning

confidence: 99%

Cancer Stem Cells in Pediatric Sarcomas

Cruz¹

2013

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…In order to effectively use ALDH1 as a CSC marker, a method known as ALDEFLUOR assay was developed to sort cells based on their ALDH1 activity 26 . Consequently, the ALDEFLUOR assay has been widely used to isolate CSC subpopulations in various tumors including different types of sarcomas 23 27 28 29 30 31 . These CSC subpopulations commonly overexpress pluripotency factors such as Sex-determining region Y-Box2 ( SOX2 ), which plays important roles in the regulation of self-renewal and tumorigenicity in CSC subpopulations of several types of cancer 32 33 34 35 36 37 .…”

mentioning

confidence: 99%

Aldh1 Expression and Activity Increase During Tumor Evolution in Sarcoma Cancer Stem Cell Populations

Martinez-Cruzado

Tornín

Santos

et al. 2016

Sci Rep

View full text Add to dashboard Cite

Tumors evolve from initial tumorigenic events into increasingly aggressive behaviors in a process usually driven by subpopulations of cancer stem cells (CSCs). Mesenchymal stromal/stem cells (MSCs) may act as the cell-of-origin for sarcomas, and CSCs that present MSC features have been identified in sarcomas due to their ability to grow as self-renewed floating spheres (tumorspheres). Accordingly, we previously developed sarcoma models using human MSCs transformed with relevant oncogenic events. To study the evolution/emergence of CSC subpopulations during tumor progression, we compared the tumorigenic properties of bulk adherent cultures and tumorsphere-forming subpopulations both in the sarcoma cell-of-origin models (transformed MSCs) and in their corresponding tumor xenograft-derived cells. Tumor formation assays showed that the tumorsphere cultures from xenograft-derived cells, but not from the cell-of-origin models, were enriched in CSCs, providing evidence of the emergence of bona fide CSCs subpopulations during tumor progression. Relevant CSC-related factors, such as ALDH1 and SOX2, were increasingly upregulated in CSCs during tumor progression, and importantly, the increased levels and activity of ALDH1 in these subpopulations were associated with enhanced tumorigenicity. In addition to being a CSC marker, our findings indicate that ALDH1 could also be useful for tracking the malignant potential of CSC subpopulations during sarcoma evolution.

show abstract

“…One of these is CD133 that has been investigated in several different cancer types, such as liposarcoma [24], glioblastoma and colorectal carcinoma [25]. In pancreatic adenocarcinoma Hermann et al [7] used CD133 in combination with CD184 to identify migratory cells essential for tumour metastasis.…”

Section: Resultsmentioning

confidence: 99%

Generation and Characterisation of Novel Pancreatic Adenocarcinoma Xenograft Models and Corresponding Primary Cell Lines

et al. 2014

Self Cite

View full text Add to dashboard Cite

Pancreatic adenocarcinoma is one of the most lethal cancer types, currently lacking efficient treatment. The heterogeneous nature of these tumours are poorly represented by the classical pancreatic cell lines, which have been through strong clonal selection in vitro, and are often derived from metastases. Here, we describe the establishment of novel pancreatic adenocarcinoma models, xenografts and corresponding in vitro cell lines, from primary pancreatic tumours. The morphology, differentiation grade and gene expression pattern of the xenografts resemble the original tumours well. The cell lines were analysed for colony forming capacity, tumourigenicity and expression of known cancer cell surface markers and cancer stem-like characteristics. These primary cell models will be valuable tools for biological and preclinical studies for this devastating disease.

show abstract

Liposarcoma cells with aldefluor and CD133 activity have a cancer stem cell potential

Cited by 22 publications

References 43 publications

Cancer Stem Cells in Pediatric Sarcomas

Cancer Stem Cells in Pediatric Sarcomas

Aldh1 Expression and Activity Increase During Tumor Evolution in Sarcoma Cancer Stem Cell Populations

Generation and Characterisation of Novel Pancreatic Adenocarcinoma Xenograft Models and Corresponding Primary Cell Lines

Contact Info

Product

Resources

About